Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Welcome to this CME-accredited CME Snapshot™ seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin/kexin type 9 (PCSK9).

Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications.

 

These activities have been supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.

Image SnapShot
Hot Topics in Dyslipidemia

From the 2018 American College of Cardiology Scientific Sessions

Deepak L. Bhatt, MD, MPH; Christopher P. Cannon, MD
MODULE 1
Begin Activity

credit amount 0.50

credit type CME

expiration 04/04/2019

Resource

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management